Sugi Predict

Sugi Predict / Compounds / SCHEMBL1655099

SCHEMBL1655099

SCHEMBL1655099

O=C(O)c1cccc(Nc2nccc(-c3cccnc3)n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 17/20 1.00
▸ BCR P11274 15/20 1.00
▸ PRKCA P17252 7/20 1.00
▸ SRC P12931 9/20 0.77
▸ PRKCD Q05655 5/20 0.76
▸ PDGFRB P09619 4/20 0.76
▸ PDGFRA P16234 4/20 0.76
▸ PRKD3 O94806 1/20 0.76
▸ PRKCG P05129 1/20 0.76
▸ PRKCB P05771 1/20 0.76
▸ PRKCH P24723 1/20 0.76
▸ PRKCI P41743 1/20 0.76
▸ PRKCE Q02156 1/20 0.76
▸ PRKCQ Q04759 1/20 0.76
▸ PRKCZ Q05513 1/20 0.76
▸ PRKD1 Q15139 1/20 0.76
▸ EGFR P00533 4/20 0.70
▸ PRKACA P17612 1/20 0.68
▸ PRKACG P22612 1/20 0.68
▸ PRKACB P22694 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14088818 0.89 ABL1 (0.80) ABL1BCRPRKCASRCPRKCD
SCHEMBL4895454 0.89 ABL1 (0.80) ABL1BCRPRKCASRCPRKCD
SCHEMBL7465138 0.89 ABL1 (0.80) ABL1BCRPRKCASRCPRKCD
SCHEMBL4902223 0.89 ABL1 (0.80) ABL1BCRPRKCASRCPRKCD
Hydrochloric Acid SCHEMBL27711429 0.88 ABL1 (0.79) ABL1BCRPRKCASRCPRKCD
SCHEMBL5379812 0.87 ABL1 (0.77) ABL1BCRPRKCASRCPRKCD
SCHEMBL1927119 0.87 ABL1 (1.00) ABL1BCRPRKCASRCPRKCD
Hydrochloric Acid SCHEMBL27708725 0.87 ABL1 (0.77) ABL1BCRPRKCASRCPRKCD
SCHEMBL9197 0.86 ABL1 (1.00) ABL1BCRPRKCASRCPRKCD
SCHEMBL210190 0.86 ABL1 (0.76) ABL1BCRPRKCASRCPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357182-B1 Inhibitors of tyrosine kinases NOVARTIS AG (CH) 2014-05-21 — — EP disclosed
EP-2606890-A1 Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer Novartis AG (CH) 2013-06-26 — — EP disclosed
US-20120252811-A1 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER BURKE GREGORY PETER (US) 2012-10-04 — — US disclosed
EP-2368889-A1 Inhibitors of tyrosine kinases Novartis AG (CH) 2011-09-28 — — EP disclosed
US-20110218187-A1 INHIBITORS OF TYROSINE KINASES BREITENSTEIN WERNER 2011-09-08 — — US disclosed
EP-2357182-A1 Inhibitors of tyrosine kinases Novartis AG (CH) 2011-08-17 — — EP disclosed
US-7956053-B2 Inhibitors of tyrosine kinases NOVARTIS AG (CH) 2011-06-07 — — US disclosed
EP-2314297-A1 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer Novartis AG (CH) 2011-04-27 — — EP disclosed
US-20090286821-A1 INHIBITORS OF TYROSINE KINASES BREITENSTEIN WERNER 2009-11-19 — — US disclosed
US-20090233905-A1 COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER NOVARTIS AG (CH) 2009-09-17 — — US disclosed
WO-2007115289-A2 COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER NOVARTIS AG (CH) 2007-10-11 — — WO disclosed
CN-101045727-A Inhibitors of tyrosine kinases NOVARTIS AG (CH) 2007-10-03 — — CN disclosed
CN-1324022-C Tyrosine kinase inhibitors NOVARTIS AG (CH) 2007-07-04 — — CN disclosed
US-20070093506-A1 Inhibitors of tyrosine kinases BREITENSTEIN WERNER 2007-04-26 — — US disclosed
US-7169791-B2 Inhibitors of tyrosine kinases NOVARTIS AG (CH) 2007-01-30 — — US disclosed
US-20060167015-A1 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) NOVARTIS AG (CH) 2006-07-27 — — US disclosed
CN-1675195-A Tyrosine kinase inhibitors NOVARTIS AG (CH) 2005-09-28 — — CN disclosed
EP-1532138-A1 INHIBITORS OF TYROSINE KINASES Novartis AG (CH) 2005-05-25 — — EP disclosed
WO-2004005281-A1 INHIBITORS OF TYROSINE KINASES NOVARTIS AG (CH) 2004-01-15 — — WO disclosed
EP-0233461-B2 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID CO (US) 2002-05-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093506-A1 Inhibitors of tyrosine kinases ABL1, BTK, FLT3 ABL1 1/4885BCR 28/4885PRKCA 273/4885
US-20110218187-A1 INHIBITORS OF TYROSINE KINASES ABL1, BTK, FLT3 ABL1 1/4885BCR 28/4885PRKCA 273/4885
US-20120252811-A1 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER KIT, ABL1, PDGFRB ABL1 2/4885BCR 8/4885PRKCA 51/4885
US-20090286821-A1 INHIBITORS OF TYROSINE KINASES ABL1, BTK, FLT3 ABL1 1/4885BCR 28/4885PRKCA 273/4885
US-20060167015-A1 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) ABL1, CDK2, CDKN1A ABL1 1/4885BCR 181/4885PRKCA 45/4885
US-20090233905-A1 COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER KIT, ABL1, PDGFRA ABL1 2/4885BCR 8/4885PRKCA 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.